Drug Delivery, Filler and Manufacturing - Clinical Research Informer

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

Drug Delivery

Filler

Manufacturing

TLC Announces Full Patient Enrollment in EXCELLENCE Trial of TLC599 for Osteoarthritis PainOn-schedule completion of enrollment despite COVID-19 pandemic; unique trial design evaluates safety and efficacy of single & repeat doses

The Pharma Data

DECEMBER 27, 2020

Current intraarticular anti-inflammatory treatments for OA have potentially toxic side effects and may lead to the destruction of cartilage filler proteins. About TLC599. An in vivo toxicity study by staining of the cartilage showed TLC599 to be cartilage sparing compared to current treatments.

Trials

Trials Clinical Trials Clinical Trials Containment

Crescita Announces Licensing Agreement for Pliaglis; in China

The Pharma Data

NOVEMBER 4, 2020

(TSX: CTX) (OTC US: CRRTF) (“Crescita” or the “Company”), a growth-oriented, innovation-driven Canadian commercial dermatology company with in-house research & development (“R&D”) and manufacturing capabilities, today announced that it has entered into an exclusive agreement with Juyou-Biotechnology Co.

Licensing

Licensing Licensing Dermatology Production

Webinars

Bridging Innovation & Patient Care: The Growing Role of AI

MORE WEBINARS

TLC Announces Full Patient Enrollment in EXCELLENCE Trial of TLC599 for Osteoarthritis PainOn-schedule completion of enrollment despite COVID-19 pandemic; unique trial design evaluates safety and efficacy of single & repeat doses

Crescita Announces Licensing Agreement for Pliaglis; in China

Webinars

Stay Connected